Key points are not available for this paper at this time.
Parents and patients have inquired about the safety and efficacy of cannabidiol (CBD) in treating child and adolescent mental health conditions. This review examines the current literature regarding CBD containing less than 0.3% tetrahydrocannabinol (THC) in treatment of childhood psychiatric disorders for youth 20 years and younger. Although there are several areas of growing interest for potential use of CBD, such as social anxiety disorder and autism spectrum disorder, the evidence base remains limited. Large-scale controlled trials are needed to determine the efficacy of CBD for treatment of child and adolescent psychiatric disorders. Psychiatr Ann . 2024;54(6):e186–e192.
Melnyk et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: